This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
by Zacks Equity Research
Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.
NVSPositive Net Change PTCTPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
by Zacks Equity Research
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change PPBTNo Net Change
biotechnology biotechs medical pharmaceuticals
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
by Zacks Equity Research
Senti Bio posts upbeat initial data from a phase I study on SENTI-202 for the treatment of relapsed/refractory hematologic malignancies. Stock soars.
SPRONegative Net Change CSTLPositive Net Change IMCRNegative Net Change SNTINegative Net Change
biotechs
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
by Zacks Equity Research
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
RHHBYPositive Net Change PFEPositive Net Change GILDNegative Net Change NVCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
by Sundeep Ganoria
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
SPRONegative Net Change ALLOPositive Net Change CSTLPositive Net Change
biotechs medical
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
by Zacks Equity Research
RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.
RDYPositive Net Change RHHBYPositive Net Change GILDNegative Net Change CHRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
by Sundeep Ganoria
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
by Zacks Equity Research
SAVA and APLT tank on pipeline and regulatory setbacks.
AMGNPositive Net Change SAVANegative Net Change APLTPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
by Zacks Equity Research
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma
by Zacks Equity Research
Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.
RDYPositive Net Change PFEPositive Net Change GILDNegative Net Change CHRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
by Zacks Equity Research
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
SPRONegative Net Change MIRMPositive Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer
by Zacks Equity Research
Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.
NVSPositive Net Change PFEPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
by Zacks Equity Research
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
PFEPositive Net Change GILDNegative Net Change ALLOPositive Net Change OTLKNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo
by Zacks Equity Research
The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.
GSKPositive Net Change SPRONegative Net Change CSTLPositive Net Change IMCRNegative Net Change
biotechs
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.
PFEPositive Net Change GILDNegative Net Change ALLOPositive Net Change APLTPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Stock Down Despite Strong Data From Obesity Drug Study
by Zacks Equity Research
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
by Zacks Equity Research
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
RHHBYPositive Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
by Zacks Equity Research
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
MRKPositive Net Change EXELNegative Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
by Zacks Equity Research
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
PFEPositive Net Change GILDNegative Net Change ACADPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
by Kinjel Shah
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechs pharmaceuticals
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
by Zacks Equity Research
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
GSKPositive Net Change BIIBPositive Net Change LLYPositive Net Change ALECNegative Net Change
biotechs
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.
AZNPositive Net Change JNJPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs medical pharmaceuticals
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
by Zacks Equity Research
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
RHHBYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
by Zacks Equity Research
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
ALNYPositive Net Change PFEPositive Net Change NTLAPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
REGNPositive Net Change NTLAPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechs